Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe.

Competing Interests: Conflict of interest: R.T. Zamanian reports grants from National Institutes of Health, Merck, United Therapeutics and GossamerBio, consultancy fees from GossamerBio, Merck and Aerovate, patents planned, issued or pending (FK-506 for treatment of PAH), participation on a data safety monitoring board or advisory board with Aerovate, and stock (or stock options) with Reviva Pharma and Genentech. J. Weatherald reports grants from Janssen, Bayer, Merck, AstraZeneca and Sanofi, consultancy fees from Janssen and Merck, payment or honoraria for lectures, presentations, manuscript writing or educational events from Janssen and Merck, payment for expert testimony from Sprigings Intellectual Property Law, support for attending meetings from Janssen and Merck, participation on a data safety monitoring board or advisory board with Janssen, Merck and Université Laval, and is member of a Medical Advisory Committee for the Pulmonary Hypertension Association of Canada and member of a Scientific Medical Advisory Committee for the Pulmonary Vascular Research Institute. B. Budhram has no potential conflicts of interest to disclose.